• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Diatide nets milestone for AcuTect

Article

Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The

Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The letter arrived exactly six months following the submission of the new drug application (NDA) to the FDA (SCAN 9/3/97).

The letter indicates that Diatide's NDA will be approved once the company clarifies certain details and formally agrees to specific postapproval requirements, according to the Londonderry, NH-based firm. Diatide expects to begin to co-market AcuTect in the U.S. with its corporate partner Nycomed Amersham immediately following approval of the agent.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.